Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK₁ receptors

C Palma¹, F Nardelli¹, S Manzini¹ and CA Maggi²

¹Menarini Ricerche, Department of Pharmacology, Via Tito Speri 10, 00040 Pomezia, RM, Italy; ²Menarini Ricerche, Via F Rismondo 12 A, 50131 Firenze, Italy

Summary
The neuropeptide substance P (SP), by stimulating tachykinin NK₁ receptors (NK₁R), triggers a number of biological responses in human glioma cell lines which are potentially relevant for tumour growth. First, radioligand binding studies demonstrated the presence of tachykinin NK₁R on SNB-19, DBTRG-05 MG and U373 MG, but not on U138 MG and MOG-G-GCM human glioma cell lines. Second, application of SP or neurokinin A (NKA) to NK₁R⁺ glioma cell lines increased the secretion of interleukin 6 (IL-6) and potentiated IL-6 secretion induced by IL-1β. SP also up-regulated the release of transforming growth factor β1 (TGF-β1) by the U373 MG glioma cell line. Third, SP induced new DNA synthesis and enhanced the proliferation rate of NK₁R⁺, but not of NK₁R⁻ glioma cell lines. Also, NKA stimulated the proliferation and cytokine secretion in NK₁R⁺ glioma cell lines. All the stimulant effects of SP/NKA on NK₁R⁺ glioma cell lines were completely blocked by a specific tachykinin NK₁R antagonist, MEN 11467. These data support the potential use of tachykinin NK₁R antagonist for controlling the proliferative rate of human gliomas.

Keywords: glioma; substance P; tachykinin NK₁ receptor; cytokine production; proliferation

Substance P (SP), an undecapeptide of the tachykinin family of peptides, is the preferential endogenous ligand for the tachykinin NK₁ receptor (NK₁R) (Maggi et al, 1993; Otsuka and Toshioka, 1993).

SP activates phospholipase C and stimulates the release of interleukin 6 (IL-6) and prostaglandin E₂ from human fetal astrocytes in culture (Palma et al, 1997), indicating an involvement of this neuropeptide in modulating astrocyte functions. Although there is little evidence for the expression of tachykinin NK₁R by astrocytes in the normal adult brain (Maggi, 1997 for review), there is evidence for up-regulation of this receptor by reactive astrocytes: proliferating glial cells express high concentrations of NK₁R after transection of the optic nerve (Mantyh et al, 1989). Moreover, SP-immunoreactive astrocytes were observed in multiple sclerosis plaques (Kostyk et al, 1989) and in the forebrains of human infants (Michel et al, 1986). Interestingly, high expression of SP receptors (Henning et al, 1995), as well as the presence of the SP itself, (Allen et al, 1985) has been described in human malignant gliomas such as astrocytomas and glioblastomas. These observations suggest a possible role of tachykinin NK₁Rs in supporting the development and growth of human astrocytomas.

The human astrocytoma cell line U373 MG expresses high levels of tachykinin NK₁R (Heuillet et al, 1993), and responds to applied SP by releasing taurine (Lee et al, 1992) and a panel of cytokines including IL-6, IL-8, leukaemia inhibitor factor (LIF) and granulocyte–macrophage colony-stimulating factor (GM-CSF) (Gitter et al, 1994; Palma et al, 1994, 1995; Palma and Manzini, 1998). The release of cytokines by malignant glioma cells has been associated with glioma progression (Gillespie, 1996); for example, IL-6 has been detected in tumour cysts and cerebrospinal fluids in patients harbouring malignant gliomas (Weller et al, 1991; Frei et al, 1992).

In addition to modulating cytokine production, SP induces DNA synthesis and activates the mitogen-activated protein (MAP) kinase pathway in U373 MG cells (Luo et al, 1996). However, the actual ability of this neuropeptide to produce proliferation of human glioma cells has not been determined until now.

In this study, we have further investigated the possible role of the tachykinin NK₁R in modulating growth/development of human astrocytomas by addressing: (a) the expression of high-affinity tachykinin NK₁R in different human glioma cell lines; (b) the presence/absence of functional responses (IL-6 secretion, DNA synthesis) to applied tachykinins in glioma cell lines positive or negative for expression of the tachykinin NK₁R (NK₁R⁺ and NK₁R⁻ respectively); (c) the ability of SP to induce not only DNA synthesis but also actual proliferation of human glioma cells; (d) whether applied tachykinins induce the secretion of immunosuppressive cytokines (IL-10 and TGF-β1) from human gliomas; (e) the possibility that neurokinin A (NKA), which is often co-expressed with SP in the central nervous system, may affect glioma cells in the same way as SP does; and (f) the effect of a potent and selective antagonist for tachykinin NK₁R on the responses of human glioma cells to SP.

MATERIALS AND METHODS

Cell culture and media
Human glioma cell lines, U373 MG (astrocytoma grade III), SNB-19 (malignant glioblastoma), DBTRG-05 MG (glioblastoma multiforme), U138 MG (glioblastoma) were obtained from the
Table 1  Inhibitory effect of the tachykinin NK, receptor antagonist MEN 11467 on SP and NKA-induced mitogenic effect on human glioma cell lines

| Conditions                                      | SNB-19       | DBTRG-05 MG | U373 MG     |
|------------------------------------------------|--------------|-------------|-------------|
| Medium*                                        | 58 000 ± 4999* | 27 147 ± 2936 | 55 333 ± 8671 |
| MEN 11467 (100 nM)                             | 60 000 ± 3945 | 28 586 ± 3789 | 58 000 ± 4999 |
| SP (100 nM)                                     | 90 333 ± 6696** | 44 560 ± 3287* | 102 666 ± 8346** |
| SP (100 nM) + MEN 11467 (100 nM)               | 60 666 ± 4055 | 29 706 ± 3336 | 61 666 ± 4055 |
| NKA (100 nM)                                    | 97 333 ± 3179** | n.t.        | 111 333 ± 8830** |
| NKA (100 nM) + MEN 11467 (100 nM)              | 62 666 ± 4115 | n.t.        | 60 666 ± 7115 |

*Human glioma cell lines, SNB-19, DBTRG-05 MG and U373 MG, were plated at 20 000 cells per well in appropriate medium containing 0.5%, 0.2% and 0.8% FBS respectively. Tachykinins and MEN 11467 were then added to the culture. After 72 h of incubation for DBTRG-05 MG and SNB-19 and 96 h for U373 MG, the cell numbers in the well were counted. bMean of cell numbers FBS respectively. Tachykinins and MEN 11467 were then added to the culture. After 72 h of incubation for DBTRG-05 MG and SNB-19 and 96 h for U373 MG, the cell numbers in the well were counted. cMean of cell numbers ± s.e.m. of a triplicate. *P < 0.05 Anova one-way and Tukey test vs medium. **P < 0.01 Anova one-way and Tukey test vs medium. n.t., not tested.

American Type Culture Collection (Rockville, MD, USA); MOG-G-CCM (anaplastic astrocytoma) were purchased from ECACC (Salisbury, Wiltshire, UK). Cells were maintained in the appropriate media [U373 MG in RPMI-1640; SNB-19 in Ham’s F10; U138 MG in Eagle’s modified Eagle medium (MEM) with 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and Earle’s balanced salt solution (BSS); MOG-G-CCM in Ham’s F10/Dulbecco’s modified Eagle medium (DMEM) (1:1); DBTRG-05 MG in RPMI-1640 with 10 mg ml–1 of adenine (Sigma, St Louis, MO, USA), 1 mg ml–1 of adenosine triphosphate (Sigma), 100 mg ml–1 of l-cystine, 15 mg ml–1 of hypoxanthine, 50 mg ml–1 of l-isoleucine, 50 mg ml–1 l-proline, 100 mg ml–1 sodium pyruvate and 1 mg ml–1 of thymidine] containing 10% heat-inactivated (65°C, 30 min) fetal bovine serum (FBS) with 5 mM HEPES, 2 mM l-glutamate, 100 U ml–1 of penicillin and 100 μl ml–1 of streptomycin. All reagents, except those otherwise indicated, were purchased from Gibco, Grand Island, NY, USA.

Reagents

Substance P, septide and NKA were purchased from Calbiochem-Novabiochem, Laufelfingen, Switzerland; lipopolysaccharide (LPS) from Escherichia coli 0111:B4 were obtained from Sigma; human recombinant IL-1β (specific activity 1.3×107 U mg–1) was purchased from Janssen Biochimica, Beerse, Belgium. The compound MEN 11467 [indolyl-3-carboxy-cis g2 Ac6c-D-2-Nal-NMe-CO-CH(4-CH3)phenyl] was synthesized in the Department of Chemistry of Menarini Ricerche, Pomezia, Italy. MEN 11467 is a potent, selective and specific ligand of human tachykinin NK1R.

In binding studies, MEN 11467 showed high affinity for NK1Rs expressed in human cell lines (Ki = 0.4 ± 0.1 and Ki = 1.34 ± 0.32 for IM-9 and U373 MG respectively) and virtually no affinity (Ki ≥ 10 000 nM) for the NK1R present in rat urinary bladder membranes, a result more than 1000-fold selective for the human compared with the murine receptors. In addition, MEN 11467 has negligible effects on the binding of [125I]NKA to hamster urinary bladder membranes (NK1 receptor) or of [3H]senktide to guinea pig cerebral cortex membranes (NK1 receptor) (Cirillo et al, 1998).

Binding assays

Binding assays were conducted on confluent intact cells in 24-well plastic culture dishes, as described previously (Goso et al, 1994) with minor modifications. Briefly, cells were rinsed and 500 μl of RPMI-1640 supplemented with 0.2% glucose and 1% bovine serum albumin was added to each well for 30 min. The buffer was then aspirated and fresh buffer containing [3H]SP (specific activity 40 Ci mmol–1; Amersham, Buckinghamshire, UK) or [3H]Sar9,Met(O2)11SP (specific activity 40.6 Ci mmol–1; New England Nuclear, Du Pont de Nemours, NEN Division, Dreieich, Germany) was added in a final volume of 500 μl. The non-specific binding was defined as that displaceable by unlabelled 10 μM SP or [Sar9,Met(O2)11]SP. The plates were incubated for 2 h at 4°C. The reaction was stopped by aspirating the medium and then rinsing each well three times with 1 ml of 0.9% sodium chloride in 10 mM HEPES (pH 7.2) wash buffer. The cells were solubilized in 5% sodium dodecyl sulphate in 0.01 M hydrochloric acid (0.5 ml) at 37°C for 1 h and radioactivity was quantified in a liquid scintillation spectrometer.

For saturation binding experiments, cells were incubated with increasing concentrations of [3H]SP (0.1–5 nm) or [3H]Sar9,Met(O2)11SP (0.1–5 nm). For competition binding experiments, cells were incubated with 2 nm of both radioligands, in the presence of varying amounts of competitor. Binding data were analysed using the iterative curve fitting program, Ligand (Munson and Rodbard, 1980).

DNA synthesis

Human glioma cells were plated on 24-well tissue culture plates (2×104 cells per well in 1 ml of medium, unless otherwise noted) in their appropriate media with low concentration or without FBS as indicated throughout the text. The stimulants were then added and left in the culture media for the entire length of the experiment. [3H]methyl-thymidine [specific activity 82.5 Ci mmol–1; Amersham, Buckinghamshire, UK] or [3H]Sar9,Met(O2)11SP (specific activity 40.6 Ci mmol–1; New England Nuclear, Du Pont de Nemours, NEN Division, Dreieich, Germany) was added in a final volume of 500 μl. The non-specific binding was defined as that displaceable by unlabelled 10 μM SP or [Sar9,Met(O2)11]SP. The plates were incubated for 2 h at 4°C. The reaction was stopped by aspirating the medium and then rinsing each well three times with 1 ml of 0.9% sodium chloride in 10 mM HEPES (pH 7.2) wash buffer. The cells were solubilized in 5% sodium dodecyl sulphate in 0.01 M hydrochloric acid (0.5 ml) at 37°C for 1 h and radioactivity was quantified in a liquid scintillation spectrometer.

For saturation binding experiments, cells were incubated with increasing concentrations of [3H]SP (0.1–5 nm) or [3H]Sar9,Met(O2)11SP (0.1–5 nm). For competition binding experiments, cells were incubated with 2 nm of both radioligands, in the presence of varying amounts of competitor. Binding data were analysed using the iterative curve fitting program, Ligand (Munson and Rodbard, 1980).

Proliferation studies

Human glioma cells were plated on 24-well tissue culture plates (2×104 cells per well in 1 ml of medium, unless otherwise noted)
in their appropriate media in serum-free conditions or with low-concentration FBS as indicated. The stimulants were then added and left in the culture medium for the entire experiment length. At the end of each experimental point, the medium was aspirated and the living cells detached with 200 μl of trypsin. The cells were then diluted in the vital colorant trypan blue (1:1) and counted in haemocytometer counting chambers (Newbauer and Nageotte).

Detection of IL-6, IL-10 and TGF-β1 in supernatants of human glioma cell lines

Glioma cells were detached by trypsinization, washed in serum-free RPMI-1640, seeded in their appropriate FBS medium at 3.5×10⁶ cell per well in 24-well culture plates, and allowed to adhere for 24 h at 37°C. Then the cultured medium was removed, the cells were washed three times in serum-free RPMI-1640, and fresh media containing low (1%) or high (10%) FBS were added. Cells were cultured for 18 h, unless otherwise indicated, in the presence or absence of SP, NKA, IL-1β. When necessary, the NK₁ receptor antagonists were co-administered with the stimulants. In all experimental conditions, cell viability was always greater than 99%, as determined by the Trypan Blue exclusion method. After the incubation time, the supernatants were collected and spun free of cells and debris. IL-6, IL-10 and TGF-β1 levels were assayed by specific ELISA kits (Quantikine, Research and Diagnostic System, Minneapolis, MN, USA or Biotrak, Amersham). To activate latent TGF-β1 to the immunoreactive form, 0.5 ml of cell culture supernatants were incubated for 10 min at room temperature with 0.1 ml 1 N hydrochloric acid. The acidified samples were then neutralized by adding 0.1 ml 1.2 N sodium hydroxide/0.5 M HEPES before being assayed. Significant levels of latent TGF-β1 were found in FBS, whereas no IL-6 or IL-10 was detected in FBS media even when FBS was present at 10%.

The data were analysed using linear regression of the Scatchard analysis of specific [³H]SP binding to human glioma cell lines. Data for Scatchard plots are from one experiment representative of three independent experiments.

**RESULTS**

**Identification and characterization of SP binding sites (NK₅R) on human glioma cell lines**

By studying the specific binding of [³H]SP, evidence for expression of tachykinin NK₅R was obtained for SNB-19 and DBTRG-05 MG cell lines in addition to U373 MG cells. In these cell lines, the specific binding of [³H]SP was usually >80% of total binding, as defined in the presence of 10 μM unlabelled SP. The binding of [³H]SP was saturable and Scatchard analysis indicated a single population of high-affinity binding sites: the $K_a$ and $B_{max}$ values obtained in the three cell lines are reported in Figure 1 along with the corresponding Scatchard plots.

Because the presence of tachykinin NK₅R in SNB-19 and DBTRG-05 MG cell lines was not studied previously, saturation binding assays with the synthetic NK₅R selective ligand [³H][Sar⁹,Met(O₂)¹¹]SP were also performed in these cell lines. Scatchard analysis showed again a single population of high-affinity binding sites ($K_a$ of 0.12 ± 0.02 nM and $B_{max}$ of 15 119 ± 1469 binding sites per cell).

Specific binding of [³H]SP or [³H][Sar⁹,Met(O₂)¹¹]SP was not observed in U138 MG and MOG-G-CCM cells, indicating that these human glioma cell lines do not express typical NK₅R.
SP and NKA stimulate the release of IL-6 from NK1R+ glioma cell lines

SNB-19 and U373 MG glioma cell lines are able to spontaneously release IL-6, not only in medium containing high-concentration FBS (10%) (Gitter et al., 1994; Palma et al., 1994, 1995; Palma and Manzini, 1998) but also when cultured in low-concentration FBS (1%) (Figure 2). Even in the more stringent culture conditions, SP and NKA induced a concentration-dependent release of IL-6. The EC_{50} values were 2 ± 0.4 and 3.8 ± 0.5 nM for SP in SNB-19 and U373 MG glioma cells, respectively; the corresponding EC_{50} values for NKA were about tenfold higher than for SP (37 ± 9 and 26 ± 7 nM for U373 MG and SNB-19 cells, respectively).

DBTRG-05 MG cells, which do not spontaneously secrete IL-6, did not respond with augmented IL-6 secretion to added SP (n = 3). However, if challenged with IL-1β (100 U ml^{-1}), a secretion of IL-6 was established (686 ± 20 pg ml^{-1}) from DBTRG-05 MG cells; in these conditions, SP produced a concentration-dependent potentiation of the response to IL-1β (739 ± 2, 893 ± 22, 1105 ± 26 and 1186 ± 15 pg ml^{-1} at 1, 10, 100 and 1000 nM of SP, respectively).

The involvement of the tachykinin NK_{1}R in the stimulant action of SP on basal or stimulated (in DBTRG-05 MG cells) secretion of IL-6 was confirmed by studying the inhibitory action of the potent and selective tachykinin NK_{1}R antagonist MEN 11467 (Figure 3). MEN 11467 produced a concentration-dependent and comparable inhibition of the responses to SP in the three NK_{1}R+ glioma cell lines.
with IC₅₀ values of 0.8 ± 0.1, 0.6 ± 0.2 and 0.6 ± 0.3 nM for U373 MG, SNB-19 and DBTRG-05 MG cells, respectively (Figure 3).

On its own, MEN 11467 neither significantly affected the basal secretion of IL-6 from SNB-19 and U373 MG cell lines (486 ± 26 and 420 ± 49 pg ml⁻¹; 900 ± 16 and 843 ± 11 pg ml⁻¹ in the absence or presence of 100 nM MEN 11467 for SNB-19 and U373 MG cells respectively), nor the IL-6 secretion induced by IL-1β from DBTRG-05 MG cells (690 ± 17 pg ml⁻¹ and 604 ± 11 pg ml⁻¹ in the absence or presence of 100 nM MEN 11467, respectively).

To confirm the specificity of the stimulatory effects of SP, the effect of this peptide was also investigated in NK1R– glioma cell lines; up to 100 nM SP neither induced IL-6 secretion nor affected IL-1β-stimulated IL-6 release from U138 MG or MOG-G-CCM cells (data not shown, n = 2 for each cell line).

**SP stimulates the production of TGF-β1 but not IL-10 from U373 MG cells**

The possible secretion of immunodepressant cytokines, IL-10 and TGF-β1, was investigated in U373 MG cells. No spontaneous secretion of IL-10 was measured nor any secretory response was observed upon challenge with IL-1β (100 U ml⁻¹), LPS (1–20 ng ml⁻¹) and SP (1–1000 nM) for 24–72 h in the presence of low- (1%) or high-concentration (10%) FBS (n = 3).

In contrast, a spontaneous release of the inactive form of TGF-β1 was detected (1033 ± 92 pg ml⁻¹) after 24 h of culture in the absence of serum. U373 MG cells (20 000 cells per well) were stimulated in serum-free medium with SP (10 or 100 nM), and at the indicated time points the number of cells in the well were counted by haemocytometer counting chamber (A) or [³H]methyl-thymidine incorporation into DNA was measured (B). [³H]methyl-thymidine was added to the cell culture for the last 24 h of incubation. Data are presented as means±s.e.m. of triplicate determination of one representative experiment. *P < 0.05 Anova one-way and Tukey test vs medium. **P < 0.01 Anova one-way and Tukey test vs medium

---

**Figure 5** SP effects on U373 MG cellular growth. U373 MG cells (20 000 cells per well) were stimulated in serum-free medium with SP (10 or 100 nM), and at the indicated time points the number of cells in the well were counted by haemocytometer counting chamber (A) or [³H]methyl-thymidine incorporation into DNA was measured (B). [³H]methyl-thymidine was added to the cell culture for the last 24 h of incubation. Data are presented as means±s.e.m. of triplicate determination of one representative experiment. *P < 0.05 Anova one-way and Tukey test vs medium. **P < 0.01 Anova one-way and Tukey test vs medium

---

**SP effects on SNB-19 and DBTRG-05 MG cellular growth.** SNB-19 cells (A) (20 000 cells per well) in serum-free medium or DBTRG-05 MG cells (B) (20 000 cells per well) in medium containing FBS at 0.2% were stimulated with SP (10 or 100 nM). At the indicated time points, the number of cells in the well were counted by haemocytometer counting chamber. Data are presented as means±s.e.m. of triplicate determination of one representative experiment. *P < 0.05 Anova one-way and Tukey test vs medium. **P < 0.01 Anova one-way and Tukey test vs medium
presence of low-concentration FBS (1%). SP potentiated, in a concentration-dependent manner, the secretion of the inactive form of TGF-β1 (Figure 4A). This response involves the activation of tachykinin NK,R because MEN 11467 (100 nm) completely blocked the SP (100 nm)-stimulated release of TGF-β1 (Figure 4B). However, the presence of active TGF-β1 molecules was never observed in the supernatants of SP-triggered U373 MG cells. TGF-β1 release was not modulated by stimulation with LPS (20 ng ml⁻¹) or IL-1β (100 U ml⁻¹).

**SP induces DNA synthesis and proliferation in NK,R-glioma cell lines**

The aim of these experiments was to verify the ability of SP to stimulate growth of human glioma cell lines by measuring both DNA synthesis (assessed by evaluating thymidine uptake) and cell proliferation (by counting the number of cells at different times from exposure to SP).

In a first series of experiments (Figure 5), U373 MG cells were plated at low concentration (2x10⁴ cells per well in 24-well tissue culture plates) in serum-free medium, and time course experiments were performed in the presence of SP. No significant increase in the number of cells was observed in control conditions (Figure 5); SP (10–100 nm) increased DNA synthesis already after 24 h of stimulation, whereas the number of cells present in the wells at this time was similar for treated and untreated samples. However, the addition of SP determined a doubling of cell number after 48 h of culture (Figure 5).

In another series of experiments (Figure 6), the ability of SP to stimulate the growth of U373 MG cells was determined in the presence of low-concentration serum (0.8%), which stimulates cell growth to some extent; as shown in Figure 6, a stimulant action of SP on cell number above the spontaneous growth was observed since 96 h from addition of the neuropeptide and a stimulant effect was evident up to 192 h (Figure 6). In these conditions, the mitogenic effect of SP was not concentration-dependent (1–1000 nm); the proliferative response observed at 1 nm was similar to that obtained at the highest concentration (55 333 ± 8671, 94 000 ± 11 222 and 102 000 ± 6060 cells per well after 96 h of incubation in medium alone, SP 1 nm and SP 1000 nm, respectively).

A third series of experiments showed (Figure 7) that application of SP determines a mitogenic effect on other NK,R-human glioma cell lines, SNB-19 and D805-MG cell lines. In contrast, the NK,R- cell lines U138 MG and MOG-G-CCM did not show any increase in DNA synthesis (after 48 h of stimulation, data not shown, n = 2 for each cell line) or proliferation after challenge with SP (55 000 ± 4582 and 61 666 ± 7023 cells per well; 81 000 ± 11 357 and 77 000 ± 4582 cells per well after 96 h of incubation in absence or in the presence of 100 nm SP for U138 MG and MOG-G-CCM, respectively).

**An NK,R antagonist inhibits SP-induced growth in glioma cell lines**

The tachykinin NK,R antagonist MEN 11467 (100 nm) completely reverted the SP-induced thymidine uptake by U373 MG cells, whereas that induced by IL-1β (10 and 40 U ml⁻¹) was not significantly reduced (Figure 8). Moreover, the enhanced proliferation of NK,R-glioma cell lines induced by SP was inhibited by MEN 11467 (Table 1).

**NKA stimulates glioma cell growth via tachykinin NK,Rs**

Like SP (Figure 5), NKA increased the thymidine uptake in U373 MG cells (38 476 ± 870, 56 855 ± 2794 and 71 827 ± 3949 d.p.m., after 24 h culture in serum-free medium, NKA 10 nm and NKA 100 nm, respectively). Moreover, in experiments performed in media containing low-concentration serum (0.8%), NKA (100 nm) stimulated the proliferation of SNB-19 cell and U373 MG cell lines (Figure 7 and Table 1). The mitogenic effect of NKA was completely blocked by MEN 11467 (Table 1).

**DISCUSSION**

The present findings expand previous observations (Luo et al., 1996; Sharif et al., 1996) on the role played by tachykinins (via NK,R) in producing biological responses which are potentially relevant for the development and growth of human gliomas. In particular, the present study provides the following novel observations: (a) in addition to U373 MG cells, two glioma cell lines have been characterized as being NK,R- (SNB-19 and D805-MG), whereas two other cell lines were found to be NK,R+ (MOG-G-CCM and U138 MG); (b) the demonstration of the mitogenic properties of SP in terms not only of DNA synthesis but also as an actual increase in glioma cell number; (c) a positive correlation has been established between functional responses (modulation of IL-6 secretion and proliferation) of human glioma cell lines and the expression of NK,R; (d) in keeping with the above, the activation of human glioma cell lines by tachykinins was blocked by the highly potent and selective tachykinin NK,R antagonist MEN 11467; (e) in addition to SP, NKA also stimulates cytokine secretion and enhances proliferation in human glioma cell lines via the NK,R; (f) stimulation of the NK,R also determines the release of the immunosuppressive cytokine TGF-β1 from the U373 MG cell line.

Application of SP or of tachykinin NK,R selective agonists determines a number of functional responses in U373 MG glioma cells: the stimulation of phosphatidyl inositol (Pi) turnover,
Also stimulates the growth of human glioma cells via the NK1R. The present findings demonstrate that, in addition to SP, NKA also stimulates the growth of human glioma cells via the NK1R. This observation is of particular interest because it provides an additional mechanism through which tachykinins may facilitate the growth and development of human gliomas. TGF-β1 and IL-6 contribute to the general immunodepression observed in glioma patients (Roszman et al., 1991; Ausiello et al., 1991). IL-6 inhibits the secretion of IL-1β and TNF-α and can counteract the activation of the immune system in this way (Schindler et al., 1990). TGF-β1 induces apoptosis of tumour-infiltrating lymphocytes, significantly reducing their cytotoxic properties, and depresses the activity of natural killer cells (Bodmer et al., 1989; Weller et al., 1995). Therefore, a stimulation by tachykinins of the local release of immunosuppressant cytokines could play a facilitatory role in the growth and development of gliomas by helping tumour cells to evade attack by the immune system.

High-grade human malignant glioma are inevitably lethal neoplasms, and the median survival of patients treated with standard cytoreductive surgery and post-operative radiotherapy is in the range of 1 year. The task of developing additional or novel treatments crucially requires an increase in knowledge of the physiology and molecular biology of these brain tumours. We have gathered evidence indicating that tachykinins (SP and NKA), through a specific stimulation of NK1R, have functional effects on several human glioma cell lines, resulting in proliferation, mitogenesis and release of soluble factors which can influence the tumour cell–host interactions including modulation of the immune system. Altogether, these observations suggest a possible role of tachykinins, via NK1Rs in glioma development and growth. It should be noted that SP was found in human glioma tissues (Allen et al., 1985), and human astrocytes themselves are a possible source of tachykinins (Michel et al., 1986). In addition, an overexpression of NK1Rs seems to occur in gliomas in relation to their degree of malignancy (Henning et al., 1995). Therefore, an autocrine/paracrine loop providing a facilitatory input on tumour growth could be devised to exist in the glioma itself. In addition, the expression of NK1Rs in peritumoral and tumoral blood vessels (Henning et al., 1995) suggests a role of SP in facilitating tumour blood supply by virtue of its NK1R-mediated angiogenic and vasodilator properties (Ziche et al., 1990). Tachykinins are multifaceted factors for amplification of the malignant growth of human glioma cells. In view of the obligatory role of NK1Rs in all these effects of tachykinins, the pharmacological blockade of NK1Rs could represent a new strategy to slow down glioma tumour growth in humans.

REFERENCES

Allen JM, Hoyle NR, Yeats JC, Gheati MA, Thomas DG and Bloom SR (1985) Neuropeptides in neurological tumours. J Neurooncol 3: 197–202
Ausiello CM, Palma C, Maleci A, Spagnoli GC, Amicis C, Antonelli G, Cusciani CU and Cassone A (1991) Cell-mediated cytotoxicity in glioma patients: analysis of effector cells and lymphokines production induced by microbial antigen in peripheral blood mononuclear cells. Eur J Cancer 27: 646–650
